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Volume 6Available online XXXAs the liver is vital for the metabolism of many anticancer drugs, determining the correct starting doses in cancer
patients with liver impairment is key to safe prescription and prevention of unnecessary adverse effects. Clinicians
typically use liver function tests when evaluating patients; however, prescribing information and summaries of
product characteristics often suggest dosing of anticancer drugs in patients with liver impairment based on the
Child-Pugh criteria, even though the criteria were not developed for this purpose. In this review, we assessed all the
oncological small molecule and cytotoxic drugs approved by the United States Food and Drug Administration (FDA)
over a 5-year period from 2014 to 2018. The various entry criteria related to these drugsdwith respect to hepatic
functiondin key pivotal studies were compared with their approved dosing recommendations found in prescribing
information and summaries of product characteristics. We found that 46% of drugs have dosing recommendations
based on Child-Pugh criteria alone, despite the fact that only 8% of these drugs were tested within studies that
used the Child-Pugh criteria as entry criteria. Moreover, we note that the data used to make recommendations
based on Child-Pugh criteria are typically from small studies that may lack an appropriate patient population. We
propose that these findings, along with details surrounding the development of the Child-Pugh criteria, call into
question the validity and appropriateness of using Child-Pugh criteria for dosing recommendations of anticancer drugs.
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The liver is critically important for the metabolism and
excretion of many anticancer drugs1,2 and liver disease and/
or liver impairment in patients with cancer can alter drug
pharmacokinetics, necessitating dose modification. Depend-
ing on the drug administered, impairment may slow the
breakdown of active or toxic metabolites (i.e. increasing drug
toxicity) or the activation of prodrugs (i.e. decreasing drug
effectiveness).3 Additionally, varying etiologies of liver
impairment, such as liver metastases, previous anticancer
treatments, cirrhosis, or hepatitis, may differently impact the
pharmacokinetics of drugs.3,4 The narrow therapeutic index
of many anticancer drugs,5 the possible toxicities from
incorrect dosing, and the potential loss of efficacy fromondence to: Prof. Carlo Palmieri, Department of Molecular and Clin-
Medicine, Systems, Molecular and Integrative Biology, University of
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- Issue 3 - 2021underdosing, all demonstrate the importance of determining
the correct starting dose of drugs in patients with cancer and
liver impairment.
The European Medicines Agency (EMA) and United States
Food and Drug Administration (FDA) have both recognized
the lack of optimal biomarkers that can be used to define
categories of liver impairment with respect to effects on
drug pharmacokinetics.6,7 Despite extensive efforts, no
single measure or group of measures has gained wide-
spread clinical use for the estimation of how hepatic
impairment will affect drug pharmacokinetics and/or phar-
macodynamics in a given patient.6,7 As such, the EMA and
FDA have allowed the use of the Child-Pugh criteria
(Supplementary Table S1, available at https://doi.org/10.
1016/j.esmoop.2021.100162)6,7 to categorize the degree
of patients’ hepatic impairment. An important caveat in the
EMA and FDA guidelines is that liver impairment must be
the cause of alterations in Child-Pugh components (i.e. cli-
nicians should rule out other underlying disease processes
as the cause of Child-Pugh alterations).6,7 However, the
causality of changes in parameters contributing to Child-
Pugh score can be difficult to discern in the context of
cancer. The EMA guidance also makes it clear thathttps://doi.org/10.1016/j.esmoop.2021.100162 1
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purposes if a study includes patients with an adequate
range of serum albumin concentrations (decreased from
normal), as well as bilirubin concentrations and prothrom-
bin times (increased from normal).6
The Child-Pugh criteria are composed of clinical and
biochemical features (including encephalopathy, ascites,
serum albumin level, serum bilirubin level, and interna-
tional normalized ratio; Supplementary Table S1, available
at https://doi.org/10.1016/j.esmoop.2021.100162).8 These
criteria were originally developed to assess operative risk in
patients undergoing surgical portosystemic shunt due to
chronic liver disease and are now routinely used as a
prognostic measure in patients with chronic liver disease
and cirrhosis.8 As such, these criteria were not designed or
validated for finessing the dosing of systemic cancer ther-
apies in patients with liver dysfunction secondary to met-
astatic cancer. Despite the known weaknesses associated
with Child-Pugh criteria, the FDA and EMA guidance for
dosing in patients with liver impairment is often charac-
terized using Child-Pugh criteria. Notably, others have crit-
icized the clinical applicability of information provided per
FDA or EMA guidance for patients with cancer and hepatic
impairment within the prescribing information (in the
United States) and summaries of product characteristics
(SmPCs; in Europe).9,10
In this narrative review, we aimed to identify which
criteria (Child-Pugh or other) were used within the pre-
scribing information or SmPCs to guide dosing recommen-
dations of 39 oncologic drugs, and whether these criteria
were supported by peer-reviewed pharmacological studies.
In doing so, we explored the differences between criteria
used for approved dosing recommendations in prescribing
documents with hepatic function inclusion criteria within
the pivotal clinical trials (i.e. those trials referred to within
those same prescribing information documents or SmPCs).METHODS
This review was designed to assess all oncologic small
molecule and cytotoxic drugs approved by the FDA over a
selected 5-year period from 2014 to 2018. This list of
treatments was derived from the FDA website. For each
drug, guidance regarding prescribing and dosing in the
presence of liver impairment was collated from prescribing
information (FDA) and SmPCs (EMA; where available).
Pivotal studies referred to within the prescribing informa-
tion and SmPCs were reviewed to identify inclusion and
exclusion criteria related to liver function used for each
drug; if available (i.e. published with the manuscript), the
protocols of clinical studies were reviewed to ensure
that complete and detailed criteria were obtained
(Supplementary Table S2, available at https://doi.org/10.
1016/j.esmoop.2021.100162). Pharmacokinetic studies in
the prescribing information and SmPCs were included in
this narrative review if Child-Pugh criteria were used in the
studies. Additionally, searches were made on PubMed for
articles published before 30 March 2019. These searches2 https://doi.org/10.1016/j.esmoop.2021.100162included the name of each drug AND ‘Child Pugh’; addi-
tional searches used the name of each drug AND ‘liver
function.’ Papers assessing the effects of liver impairment
on drug dosing were reviewed if they met the following
criteria: (i) Child-Pugh criteria were used as the inclusion
criteria and (ii) studies were published in English. Any
relevant information or studies (published in English)
regarding the use of Child-Pugh criteria referred to within
the prescribing information or SmPCs were also reviewed. A
separate search on clinicaltrials.gov was completed to
identify pharmacokinetic studies that may not have been
included in the PubMed search. Studies from this search are
included in Supplementary Table S3, available at https://
doi.org/10.1016/j.esmoop.2021.100162, irrespective of the
liver impairment criteria used; studies were recorded irre-
spective of the results of the PubMed search. The search
terms used to search clinicaltrials.gov were the drug name
AND ‘Child-Pugh’ OR ‘liver impairment’ OR ‘hepatic
impairment’. If the published studies were not directly
identified on clinicaltrials.gov, then the NCT numbers for
these studies were used to locate any corresponding pub-
lications. Data searches and extraction were carried out by
IRM and CP.Patient and public involvement statement
Due to the procedures needed to conduct this review, it was
not considered a suitable option to include patient/public
involvement.
RESULTS
Overview of oncologic small molecule and cytotoxic drugs
approved by the FDA
From 2014 to 2018, 39 oncologic small molecule and
cytotoxic drugs were approved by the FDA (Supplementary
Table S2, available at https://doi.org/10.1016/j.esmoop.
2021.100162). Of these drugs, lenvatinib was approved
for three indications (locally recurrent or metastatic, pro-
gressive, radioactive iodine-refractory differentiated thyroid
cancer; first-line treatment of patients with unresectable
hepatocellular carcinoma (HCC); and in combination with
everolimus, for the treatment of patients with advanced
renal cell carcinoma following one prior antiangiogenic
therapy. All other drugs were approved for a single indica-
tion during the defined time period. Indications spanned 13
broad categories (Figure 1); 14 drugs were approved to
treat blood cancers, six were approved to treat lung can-
cers, and five were approved for use in breast cancer
(Figure 1). No more than four drugs were approved for each
remaining category of cancer (i.e. gynecologic, liver, kidney,
soft tissue, pancreas, skin, colorectal, thyroid, prostate, and
solid tumors) (Figure 1).Dosing guidance for patients with liver impairment:
prescribing information and SmPCs
According to the prescribing information and SmPCs of the
39 oncologic small molecule and cytotoxic drugs examined,Volume 6 - Issue 3 - 2021
Figure 1. FDA-approved (2014-2018) oncologic small molecule and cytotoxic drugs by broad indication. Some therapies are indicated for >1 cancer. Some therapies
are used in combination with other therapies (combination therapy is not listed in the figure).
FDA, United States Food and Drug Administration.
a Includes lymphoma, leukemia, and myeloma.
b Includes liposarcoma, and leiomyosarcoma.
c Includes solid tumors that: have neurotrophic receptor tyrosine kinase gene fusion without a known acquired resistance mutation; are metastatic or where surgical
resection is likely to result in severe morbidity; have no satisfactory alternative treatments or that have progressed following treatment.
d Two formulations are available: Cabometyx® and Cometriq®; Cabometyx obtained approval for renal cell carcinoma between 2014 and 2018, approval for hepato-
cellular carcinoma occurred in 2019; FDA approval of Cometriq occurred before 2014.
e Encorafenib and binimetinib are indicated in combination.
f Lenvatinib in combination with everolimus.
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impairment were based on liver function tests alone for
26% (10/39) of drugs and Child-Pugh scores alone for 46%
(18/39) of drugs (Figure 2; Supplementary Table S2, avail-
able at https://doi.org/10.1016/j.esmoop.2021.100162).
Guidance was not specified (i.e. criteria defining liver
impairment were not specified or specific guidance was not
given) for 13% (5/39) of drugs; and guidance was based on
both Child-Pugh scores and liver function tests for the
remaining drugs (15%; 6/39) (Figure 2; SupplementaryVolume 6 - Issue 3 - 2021Table S2, available at https://doi.org/10.1016/j.esmoop.
2021.100162).
Recommendations from the FDA and EMA are summa-
rized separately because 7 of the 39 treatments did not
have publicly available SmPCs at the time of manuscript
preparation (August 2020). Based on the various drugs’
prescribing information (FDA) documents, 31% (12/39) of
drugs had recommendations based on liver function tests
alone, 38% (15/39) had recommendations based on Child-
Pugh scores alone, and the criteria for recommendationshttps://doi.org/10.1016/j.esmoop.2021.100162 3
Criteria (%) FDA (Mb [ 39) EMA (Mb [ 32) FDA and EMA (Mb [ 39)
Child-Pugh (only) 15 (38) 20 (63) 18 (46)
Liver function tests (only) 12 (31) 8 (25) 10 (26)
Both Child-Pugh and liver function tests 2 (5) 2 (6) 6 (15)c
Not specified 10 (26) 2 (6) 5 (13)
EMA, European Medicines Agency; FDA, United States Food and Drug Administration; SmPC, summary of product characteristics.
a The following drugs did not have a publicly available SmPC (through August 2020) and therefore do not appear under the EMA or ‘both’ portions of the graph: acalabrutinib,
belinostat, copanlisib, duvelisib, enasidenib, glasdegib, and ivosidenib.
b M equals the number of approved drugs by the FDA or EMA, respectively; percentage based on the total number of drugs.
c This number refers to drugs that had dosing guidance based on both Child-Pugh and liver function test criteria; please note, this includes drugs that had dosing guidance
based on Child-Pugh criteria in the prescribing information (FDA) and liver function tests in the SmPCs (EMA) or vice versa.
Figure 2. Comparison of criteria used for dosing recommendations made by the EMA and FDA.
a
ESMO Open C. Palmieri & I. R. Macpherson(or recommendations themselves) were not specified for
26% (10/39) of drugs (Figure 2). Only copanlisib and
osimertinib had recommendations based on both Child-
Pugh scores and liver function tests (Figure 2). Of the 32
with available SmPCs, these documents included dosing
recommendations based on Child-Pugh scores alone in 63%
(20/32) of drugs and liver function tests alone in 25% (8/32)
of drugs. Specific recommendations/criteria for recom-
mendations were not explicit in 6% (2/32) of drugs, and
only osimertinib and venetoclax had recommendations for
both Child-Pugh scores and liver function tests.4 https://doi.org/10.1016/j.esmoop.2021.100162Comparison of pivotal trial data and dosing guidance
summarized in prescribing information and/or SmPCs
Of the 75 pivotal published studies referred to within the
prescribing information and SmPCs of reviewed drugs, the
full protocol was published along with the manuscript 71%
(53/75) of the time (Supplementary Table S2, available at
https://doi.org/10.1016/j.esmoop.2021.100162). Protocols,
manuscripts (where the protocols were not available), or
other sources (if the study was not published), were
reviewed to identify entry criteria related to hepatic func-
tion. Review of this information revealed that studyVolume 6 - Issue 3 - 2021
C. Palmieri & I. R. Macpherson ESMO Openprotocols referenced using Child-Pugh criteria for only 8%
(3/39) of drugs [i.e. in pivotal studies of lenvatinib,
cabozantinib, and ribociclib (exclusion criteria only)]. In the
case of lenvatinib, the Child-Pugh criteria were used in an
HCC trial protocol (REFLECT); however, liver function tests
were also used as inclusion criteria.11 For cabozantinib, the
METEOR study in renal cell carcinoma excluded patients who
were classified as having Child-Pugh class B or C; however,
inclusion criteria were based on liver function tests.12 And
although the CELESTIAL study in HCC (cabozantinib was
indicated for HCC in 2019) allowed the inclusion of patients
classified as having Child-Pugh class A, liver function tests
were also included as part of the entry criteria.13 Overall, for
92% (22/24) of drugs where Child-Pugh scores were used for
specific dosing recommendations in either the prescribing
information or SmPCs (or both), Child-Pugh criteria had not
been used in the pivotal trial.Liver impairmentdas assessed by Child-Pugh
criteriadand drug pharmacokinetics
The 24 drugs for which approved dosing recommendations
were based on Child-Pugh criteria (i.e. in prescribing in-
formation and/or SmPCs; Figure 3; those set in bold font)
all had pharmacokinetic studies in patients where liver
impairment was characterized using the Child-Pugh
criteria. However, studies for 14 of these drugs were not
published, and information on the types of patients
[i.e. patients with cancer (and what type of cancer) or
without cancer] included in these 14 studies were limited
(Figure 3). Of the remaining 10 drugs with a peer-reviewed
publication describing dosing and/or pharmacokinetics
according to the Child-Pugh criteria, only 3 drugs had
studies in patients with cancer [HCC for lenvatinib14; mixed
tumor types (including ovarian cancer) for olaparib15,16;
solid tumors for osimertinib17] (Table 1 and Figure 3).
Moreover, these peer-reviewed studies were all limited in
enrollment size (N  33 patients) (Table 1).a
a
aa
Figure 3. Summary of all pharmacokinetic studies in patients with liver impairme
Drug names in bold represent those drugs for which dosing guidelines in the prescri
a Patients were assumed to be ‘noncancer patients’ because no details on underlyin
pharmacokinetic studies.
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A variety of possible criteria may help clinicians assess liver
function in patients with cancer.1,6,28 Based on our experi-
ence and the details from the reviewed protocols within
this analysis, clinical trials of anticancer drugs have typically
defined hepatic impairmentdfor the purposes of entry
criteria and dose modificationsdaccording to baseline liver
function tests as opposed to Child-Pugh criteria
(Supplementary Table S2, available at https://doi.org/10.
1016/j.esmoop.2021.100162). Moreover, in routine onco-
logical practice, liver function tests are utilized in relation to
therapeutic decisions and drug dosing even though there is
no consensus on which criteria should be used.29 Despite
this routine use of liver function tests, the EMA and FDA
have provided guidance for the use of the Child-Pugh
criteria. As a result, among the oncologic, small molecule
and cytotoxic drugs licensed from 2014 to 2018, the Child-
Pugh criteria alone were cited in 38% of FDA prescribing
information documents and in 63% of SmPCs for EMA-
approved drugs (Supplementary Table S2, available at
https://doi.org/10.1016/j.esmoop.2021.100162).
The number of FDA and EMA dosing recommendations
based on Child-Pugh criteria alone is concerning, given that
only 8% of drugs approved by the FDA from 2014 to 2018
had pivotal trials that used the Child-Pugh criteria within
their inclusion and exclusion criteria. Moreover, only 42%
(10/24) of drugs (that used Child-Pugh criteria for dosing
recommendations in prescribing information and/or SmPCs)
had a peer-reviewed publication describing dosing and
pharmacokinetics according to Child-Pugh criteria, and all
these studies were limited in size (33 patients). In
addition, of these pharmacokinetics studies involving the
Child-Pugh criteria only 3 out of these 10 recruited patients
with cancer (Table 1; Figure 3).
Recently, Krens et al.3 put forward dosing recommenda-
tions for 160 anticancer drugs based on information derived
from prescribing information and SmPCs issued by the FDA
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Table 1. Summary of peer-reviewed pharmacokinetic studies in patients with liver impairment assessed by Child-Pugh criteria
Drug Indication Study Details
Alectinib  For the treatment of patients with anaplastic
lymphoma kinase-positive metastatic non-
small-cell lung cancer
Morcos et al. J Clin Pharmacol. 2018;58:1618-
1628.18
 Participant number: 28 (normal hepatic
function, n ¼ 12; Child-Pugh class B,
n ¼ 8; Child-Pugh class C, n ¼ 8)
 Patient characteristics: patients without cancer
Cabozantinib  Patients with progressive metastatic medul-
lary thyroid cancer
 Patients with advanced renal cell carcinoma
 Patients with hepatocellular carcinoma who
had been previously treated with sorafeniba
Nguyen et al. J Clin Pharmacol. 2016;56:1130-
1140.19
 Participant number: 26 (normal hepatic
function, n ¼ 10; Child-Pugh class A,
n ¼ 8; Child-Pugh class B, n ¼ 8)
 Patient characteristics: patients without can-
cer (not directly specified)
Dacomitinib  First-line treatment of patients with meta-
static non-small-cell lung cancer with
epidermal growth factor receptor exon 19
deletion or exon 21 L858R substitution
mutations
Giri et al. Invest New Drugs. 2015;33(4):931-
941.20
 Participant number: 25 (normal hepatic
function, n ¼ 8; Child-Pugh class A,
n ¼ 8; Child-Pugh Class B, n ¼ 9)
 Patient characteristics: patients without
cancer
Gilteritinib  Patients who have relapsed or refractory
acute myeloid leukemia with an FLT3
mutation
James et al. Clin Pharmacokinet. 2020
Oct;59(10):1273-1290.21
 Participant number: 24 (normal hepatic
function, n ¼ 8; Child-Pugh class B,
n ¼ 8; Child-Pugh class C, n ¼ 8)
 Patient characteristics: patients without liver
cancer (other types of cancer not directly
specified for exclusion)
Glasdegib  In combination with low-dose cytarabine, for
the treatment of newly diagnosed acute
myeloid leukemia (AML) in adult patients
who are 75 years old or who have
comorbidities that preclude use of intensive
induction chemotherapy
Masters et al. Clin Pharmacol Drug Dev. 2020
Dec 23.22
 Participant number: 24 (normal hepatic
function, n ¼ 8; Child-Pugh class B,
n ¼ 8; Child-Pugh class C, n ¼ 8)
 Patient characteristics: patients without
cancer
Idelalisib  Relapsed chronic lymphocytic leukemia, in
combination with rituximab, in patients for
whom rituximab alone would be considered
appropriate therapy because of other
comorbidities
 Relapsed follicular B-cell non-Hodgkin’s lym-
phoma in patients who have received at
least 2 prior systemic therapies
 Relapsed small lymphocytic lymphoma in pa-
tients who have received at least 2 prior
systemic therapies
Jin et al. J Clin Pharmacol. 2015;55:944-952.23  Participant number: 32 (healthy matched
control, n ¼ 12; Child-Pugh class B,
n ¼ 10; Child-Pugh class C, n ¼ 10)
 Patient characteristics: patients without can-
cer (not directly specified)
Ivosidenib  Adult patients with relapsed or refractory
acute myeloid leukemia with a susceptible
IDH1 mutation
Fan et al. Clin Pharmacol Drug Dev. 2021;10:99-
109.24
 Participant number: 33 (normal hepatic
function, n ¼ 16; Child-Pugh class A,
n ¼ 9; Child-Pugh class B, n ¼ 8)
 Patient characteristics: patients without
cancer
Lenvatinib  For the treatment of patients with locally
recurrent or metastatic, progressive, radio-
active iodine-refractory differentiated
thyroid cancer
 In combination with everolimus, for the
treatment of patients with advanced renal
cell carcinoma following 1 prior antiangio-
genic therapy
 For the first-line treatment of patients with
unresectable hepatocellular carcinoma
Shumaker et al. J Clin Pharmacol. 2015;55:317-
327.25
 Participant number: 26 (normal hepatic
function, n ¼ 8; Child-Pugh class A, n ¼ 6;
Child-Pugh class B, n ¼ 6; Child-Pugh class C,
n ¼ 6)
 Patient characteristics: patients without
cancer
Ikeda et al. Clin Cancer Res. 2016;22:1385-
1394.14
 Patient number: 20 patients (Child-Pugh
class A, n ¼ 9; Child-Pugh class B, n ¼ 11)
 Patient characteristics: patients with
advanced hepatocellular carcinoma
Olaparib  For the maintenance treatment of adult pa-
tients with recurrent epithelial ovarian, fal-
lopian tube, or primary peritoneal cancer,
who are in a complete or partial response to
platinum-based chemotherapy
 For the treatment of adult patients with
deleterious or suspected deleterious germ-
line BRCA-mutated advanced ovarian cancer
who have been treated with 3 or more prior
lines of chemotherapy
Rolfo et al. Pharmacokinetics and safety of
olaparib in patients with advanced solid
tumours and hepatic or renal impairment. In
18th Annual Meeting of the American Society
for Clinical Pharmacology and Therapeutics.
13e18 March, 2017; Washington, DC.
Abst PIIe121.16
Pilla Reddy et al. Clin Pharmacol Ther.
2019;105:229-241.15
 Patient number: 23 patients (normal hepatic
function, n ¼ 13; Child-Pugh class A, n ¼ 9;
Child-Pugh class B results were ongoing at
time of abstract publication)
 Patient characteristics: major tumor types
included ovarian (17%), breast (13%), and
colon (13%) with chronic hepatic impairment
where liver metastases were not the sole
reason for any changes in liver function
Osimertinib  For the treatment of patients with metasta-
tic epidermal growth factor receptor T790M
mutation positive non-small-cell lung cancer
Grande et al. J Pharmacol Exp Ther.
2019;369:291-299.17
 Patient number: 22 (normal hepatic func-
tion, n ¼ 10; Child-Pugh class A, n ¼ 7;
Child-Pugh class B, n ¼ 5)
 Patient characteristics: patients with solid tu-
mors and chronic hepatic impairment and
where liver metastases were not the sole
reason for any changes in liver function
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Table 1. Continued
Drug Indication Study Details
Panobinostat  For the treatment of patients with multiple
myeloma in combination with bortezomib
and dexamethasone; patient must have
received 2 prior regimens, including bor-
tezomib and an immunomodulatory agent
Slingerland et al. Cancer Chemother Pharmacol.
2014 Nov;74(5):1089-1098.26
 Patient number: 25 (normal hepatic func-
tion, n ¼ 10; hepatic dysfunction: mild,
n ¼ 8; moderate, n ¼ 6; severe, n ¼ 1)
 Patient characteristics: patients with
advanced solid malignancies
Sonidegib  For the treatment of adult patients with
locally advanced basal cell carcinoma that
has recurred following surgery or radiation
therapy, or those who are not candidates for
surgery or radiation therapy
Horsmans et al. Clin Pharmacokinet.
2018;57:345-354.27
 Participant number: 33 (normal hepatic
function, n ¼ 8; Child-Pugh Class A, n ¼ 8;
Child-Pugh class B, n ¼ 8; Child-Pugh class C,
n ¼ 9)
 Patient characteristics: patients without can-
cer (not directly specified)
a This indication occurred after the primary dates considered in this study (2014-2018).
C. Palmieri & I. R. Macpherson ESMO Openwere made based on Child-Pugh score.3 We previously
highlighted the issues surrounding these recommenda-
tions.30 Briefly, Child-Pugh criteria were historically devel-
oped to assess the prognosis of patients with chronic liver
disease,8,31 and have never been validated for guiding
dosing of anticancer drugs. The use of these criteria is
further limited in patients with cancer because of the
impact that the disease can have on the individual com-
ponents of the criteriadthereby influencing a patient’s
overall Child-Pugh score.30 As clear guidance is lacking
about when the Child-Pugh criteria should be used in clin-
ical practice, its application may be arbitrary and can lead to
over- or under-dosing of cancer drugs. We propose that this
widespread use of Child-Pugh criteria fails to address the
most common clinical scenario encountered in oncological
practice, namely appropriate dose selection in a patient
with abnormal liver function secondary to metastatic
involvement of the liver. Indeed, the minority of hepatic
impairment pharmacokinetics studies that did enroll par-
ticipants with cancer specifically required the liver impair-
ment to be due to causes other than metastatic infiltration.
Pharmacokinetic analyses with gefitinib help crystallize
these issues because patients enrolled with moderate and
severe hepatic impairment due to liver metastases had no
clinically relevant differences in drug exposure; however,
patients characterized as Child-Pugh class B and C second-
ary to cirrhosis had a significant increase in gefitinib expo-
sure.4 These issues are especially concerning because it is
unclear if similar inconsistencies exist with other anticancer
treatments. The findings in our review further illustrate the
lack of evidence for dosing recommendations based solely
on Child-Pugh criteria.
The data in this review are limited by the publicly avail-
able information in study protocols and data that were
accessible in peer-reviewed publications. Therefore, data
that are held on file and not in the public domain are not
represented. Moreover, updates to prescribing information
and SmPCs may not be captured in this manuscript. Addi-
tionally, this review is not a systematic literature review, and
therefore, the studies identified were limited by the results
yielded from the selected search terms described and the
authors’ knowledge of the field. A more systematic review in
the future using searches in both PubMed and EMBASE mayVolume 6 - Issue 3 - 2021provide further clarity regarding the topics summarized in
this manuscript. Despite these limitations, this review
highlights a disconnect between the patient entry criteria
used in pivotal studies and the criteria used to suggest drug
dose modifications (which often use the upper limit of
normal of transaminase and bilirubin levels) and the
approved prescribing recommendations by the EMA and
FDA regarding dosing in the presence of liver impairment
(which often use Child-Pugh criteria). Based on the data
within this review a discussion and reappraisal of the guid-
ance contained within prescribing information and SmPCs
relating to dose modification recommendations for patients
with hepatic impairment is needed. Accepting that patients
with severe liver disease will continue to be excluded from
most pivotal studies, we nevertheless believe that SmPCs
and prescribing information should more closely reflect the
pivotal studies that lead to licensing of anticancer drugs
when providing dosing guidance. Given the large number of
patients and safety data that are accrued in pivotal studies,
it may even be argued that it is detrimental to base clinical
dosing on studies (with Child-Pugh criteria) that have limited
evidence and are conducted in small groups of highly
selected patients without cancer or with a different cancer
type than that for which the drug is approved.
Based on the findings of this review, we suggest that the
EMA and FDA review and critically appraise the appropri-
ateness and validity of using Child-Pugh criteria in the
context of anticancer drugs; moreover, all pivotal trial pro-
tocols should be published and available to guide clinical
dosing decisions. In our opinion, the utilization of hepatic
function entry criteria and dose modification criteria (which
are based on the investigational brochure and contain the
most updated pharmacokinetic data) of pivotal studies
would provide a more logical and evidence-based approach
to determine optimal dosing in patients with cancer and
liver impairment.ACKNOWLEDGEMENTS
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